Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation

Edina Pallagi, Rita Ambrus, P. Szabó-Révész, Ildikó Csóka

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Regulatory science based pharmaceutical development and product manufacturing is highly recommended by the authorities nowadays. The aim of this study was to adapt regulatory science even in the nano-pharmaceutical early development. Authors applied the quality by design (QbD) concept in the early development phase of nano-systems, where the illustration material was meloxicam. The meloxicam nanoparticles produced by co-grinding method for nasal administration were studied according to the QbD policy and the QbD based risk assessment (RA) was performed. The steps were implemented according to the relevant regulatory guidelines (quality target product profile (QTPP) determination, selection of critical quality attributes (CQAs) and critical process parameters (CPPs)) and a special software (Lean QbD Software®) was used for the RA, which represents a novelty in this field. The RA was able to predict and identify theoretically the factors (e.g. sample composition, production method parameters, etc.) which have the highest impact on the desired meloxicam-product quality. The results of the practical research justified the theoretical prediction. This method can improve pharmaceutical nano-developments by achieving shorter development time, lower cost, saving human resource efforts and more effective target-orientation. It makes possible focusing the resources on the selected parameters and area during the practical product development.

Original languageEnglish
Pages (from-to)384-392
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume491
Issue number1-2
DOIs
Publication statusPublished - Jul 17 2015

Fingerprint

meloxicam
Pharmaceutical Preparations
Software Design
Intranasal Administration
Nanoparticles
Software
Guidelines
Costs and Cost Analysis
Research

Keywords

  • Early development QbD
  • Meloxicam nanoparticles
  • Nasal administration
  • Quality by design
  • Regulatory pharmacy
  • Risk assessment

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. / Pallagi, Edina; Ambrus, Rita; Szabó-Révész, P.; Csóka, Ildikó.

In: International Journal of Pharmaceutics, Vol. 491, No. 1-2, 17.07.2015, p. 384-392.

Research output: Contribution to journalArticle

@article{5359ddc91b4340ddb63bf797b28c29cd,
title = "Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation",
abstract = "Regulatory science based pharmaceutical development and product manufacturing is highly recommended by the authorities nowadays. The aim of this study was to adapt regulatory science even in the nano-pharmaceutical early development. Authors applied the quality by design (QbD) concept in the early development phase of nano-systems, where the illustration material was meloxicam. The meloxicam nanoparticles produced by co-grinding method for nasal administration were studied according to the QbD policy and the QbD based risk assessment (RA) was performed. The steps were implemented according to the relevant regulatory guidelines (quality target product profile (QTPP) determination, selection of critical quality attributes (CQAs) and critical process parameters (CPPs)) and a special software (Lean QbD Software{\circledR}) was used for the RA, which represents a novelty in this field. The RA was able to predict and identify theoretically the factors (e.g. sample composition, production method parameters, etc.) which have the highest impact on the desired meloxicam-product quality. The results of the practical research justified the theoretical prediction. This method can improve pharmaceutical nano-developments by achieving shorter development time, lower cost, saving human resource efforts and more effective target-orientation. It makes possible focusing the resources on the selected parameters and area during the practical product development.",
keywords = "Early development QbD, Meloxicam nanoparticles, Nasal administration, Quality by design, Regulatory pharmacy, Risk assessment",
author = "Edina Pallagi and Rita Ambrus and P. Szab{\'o}-R{\'e}v{\'e}sz and Ildik{\'o} Cs{\'o}ka",
year = "2015",
month = "7",
day = "17",
doi = "10.1016/j.ijpharm.2015.06.018",
language = "English",
volume = "491",
pages = "384--392",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation

AU - Pallagi, Edina

AU - Ambrus, Rita

AU - Szabó-Révész, P.

AU - Csóka, Ildikó

PY - 2015/7/17

Y1 - 2015/7/17

N2 - Regulatory science based pharmaceutical development and product manufacturing is highly recommended by the authorities nowadays. The aim of this study was to adapt regulatory science even in the nano-pharmaceutical early development. Authors applied the quality by design (QbD) concept in the early development phase of nano-systems, where the illustration material was meloxicam. The meloxicam nanoparticles produced by co-grinding method for nasal administration were studied according to the QbD policy and the QbD based risk assessment (RA) was performed. The steps were implemented according to the relevant regulatory guidelines (quality target product profile (QTPP) determination, selection of critical quality attributes (CQAs) and critical process parameters (CPPs)) and a special software (Lean QbD Software®) was used for the RA, which represents a novelty in this field. The RA was able to predict and identify theoretically the factors (e.g. sample composition, production method parameters, etc.) which have the highest impact on the desired meloxicam-product quality. The results of the practical research justified the theoretical prediction. This method can improve pharmaceutical nano-developments by achieving shorter development time, lower cost, saving human resource efforts and more effective target-orientation. It makes possible focusing the resources on the selected parameters and area during the practical product development.

AB - Regulatory science based pharmaceutical development and product manufacturing is highly recommended by the authorities nowadays. The aim of this study was to adapt regulatory science even in the nano-pharmaceutical early development. Authors applied the quality by design (QbD) concept in the early development phase of nano-systems, where the illustration material was meloxicam. The meloxicam nanoparticles produced by co-grinding method for nasal administration were studied according to the QbD policy and the QbD based risk assessment (RA) was performed. The steps were implemented according to the relevant regulatory guidelines (quality target product profile (QTPP) determination, selection of critical quality attributes (CQAs) and critical process parameters (CPPs)) and a special software (Lean QbD Software®) was used for the RA, which represents a novelty in this field. The RA was able to predict and identify theoretically the factors (e.g. sample composition, production method parameters, etc.) which have the highest impact on the desired meloxicam-product quality. The results of the practical research justified the theoretical prediction. This method can improve pharmaceutical nano-developments by achieving shorter development time, lower cost, saving human resource efforts and more effective target-orientation. It makes possible focusing the resources on the selected parameters and area during the practical product development.

KW - Early development QbD

KW - Meloxicam nanoparticles

KW - Nasal administration

KW - Quality by design

KW - Regulatory pharmacy

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84937206737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937206737&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.06.018

DO - 10.1016/j.ijpharm.2015.06.018

M3 - Article

C2 - 26134895

AN - SCOPUS:84937206737

VL - 491

SP - 384

EP - 392

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -